Crown Bioscience

AUGUST 2, 2021

Interest in IMIDs has grown rapidly in recent years, largely fueled by the view that IMIDs share common inflammatory pathways, and therefore, there is the possibility that novel therapies that work in one IMID may work in other IMIDs.

Disease 52

Disease Drug Development Immune Response Drugs 52

Advarra

AUGUST 16, 2022

Orphan drugs have historically faced a number of barriers, such as limited research and development (R&D) investment due to an expected lack of profitability as well as challenges in clinical trial design and recruitment. Before 1983, only 38 orphan drugs had received U.S. These centers, in conjunction with the FDA and U.S.

Disease 52

Disease Clinical Trials FDA Approval FDA 52

The Pharma Data

APRIL 24, 2021

In 1999, Novartis launched the first fixed-dose Artemisinin-based Combination Therapy (ACT) and in 2009, the first dispersible pediatric ACT developed in partnership with Medicines for Malaria Venture (MMV). Novartis is advancing Research & Development of next-generation treatments to combat emerging drug resistance.

Clinical Trials 52

Clinical Trials Treatment Trials Disease 52

NIH Director's Blog: Drug Development

FEBRUARY 16, 2021

This improvement stems from several factors, including the FDA’s emergency use authorization (EUA) of a number of therapies found to be safe and effective for COVID-19. Yet the quest to save more lives from COVID-19 isn’t even close to being finished, and researchers continue to work intensively to develop new and better treatments.

Clinical Trials 52

Clinical Trials Trials Hospitals Vaccine 52

The Pharma Data

JANUARY 26, 2021

percent) in patients taking therapy and 36 events (7.0 Bamlanivimab and etesevimab together also demonstrated statistically significant improvements on all key secondary endpoints, providing strong evidence that the therapy reduced viral load and accelerated symptom resolution. who require oxygen therapy due to COVID-19, OR.

Hospitals 52

Hospitals Treatment Trials Long-Term Care Facilities 52

Agency IQ

JUNE 9, 2023

The problems: Although the current regulation stimulated orphan drug research, it didn’t do enough The regulation fostered development of medicines for rare diseases since implementation, but not enough. Additionally, the smaller potential customer base may provide an insufficient return on the investment into research.

Marketing 40

Marketing Regulations Biosimilars Drugs 40

Codon

JANUARY 21, 2024

You can do a challenge trial with deadly diseases, but you need a “rescue therapy.” When a vaccine fails, that can have downstream effects on how other researchers in the field approach their own vaccine development, and how funding gets moved around. But it's hard to find the counterfactual. That's not coincidental.

Vaccine 108

Vaccine Trials Disease Treatment 108

Codon

JUNE 2, 2024

It took another five years for a pair of American researchers to come up with an explanation before going on to pioneer the mouse as biomedicine’s premier model organism. It took another century after Mendel’s pea experiments for the mouse to become an established presence in research labs.

Laboratories 115

Laboratories Research Disease Science 115